The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

If you are a Gemini Advanced subscriber, you can access Gemini 2.0 Pro through the model-picker menu on both desktop and ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Clay Northam Wealth Management LLC increased its stake in Exxon Mobil Co. (NYSE:XOM – Free Report) by 8.4% in the fourth ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Highlights,Increased institutional ownership in Vertex Inc. with notable transactions recorded.,Strong year-over-year revenue ...

Google just dropped 4 new Gemini 2.0-series models, with some designed for coding performance and complex prompts and the ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Costello Asset Management INC raised its position in shares of Exxon Mobil Co. (NYSE:XOM – Free Report) by 25.7% in the ...